Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Fully Automated Molecular Diagnostic System

By HospiMedica staff writers
Posted on 21 Aug 2003
A new fully automated, high throughput molecular diagnostic system can be used in both clinical laboratories and blood-screening laboratories to reduce costs and improve workflow.

In a clinical trial, equivalency between the system and existing semi-automated systems was shown by using an amplified nucleic acid test (NAT) for simultaneously detecting Chlamydia trachomatis and Neisseria gonorrhoeae. More...
The Aptima Combo 2 assay of Gen-Probe, Inc. (San Diego, CA, USA; www.gen-probe.com) was used in the trial. Gen-Probe also developed the new diagnostic system, called Tigris DTS, which the company says is the first fully automated molecular diagnostic testing system.

Tigris has the ability to process up to 500 samples in an eight-hour shift and up to 1,000 samples in about 13 hours. For this reason, the system is expected to significantly reduce labor, improve efficiency and operator ergonomics, and reduce the risk of contamination associated with NAT assays. To meet these goals, Tigris is designed to integrate and automate all the steps associated with Gen-Probe's latest amplified NAT assays, including sample processing, amplification, detection, and results processing.

"Our goal now is to expand the menu of tests that can be performed on the Tigris system, including our blood screening and clinical diagnostics product lines,” said Henry L. Nordhoff, chairman, president, and CEO of Gen-Probe.




Related Links:
Gen-Probe

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.